Roche and UpFront sign agreement
Roche Vitamins has signed a global licence agreement with UpFront Chromatography, an innovative Danish technology company. Roche Vitamins will use the Expanded Bed Adsorption (EBA) technology developed by UpFront Chromatography for the production of certain ingredients for pharmaceutical, feed, food and cosmetics applications. The financial terms of the agreement were not disclosed.
EBA is a highly efficient technique for the extraction of target molecules directly from unclarified crude feedstock. Unlike traditional methods of protein isolation, EBA combines the steps into a single procedure. This technology enables the extraction of compounds that are very diluted and optimises production processes. Allan Lihme, managing director of UpFront Chromatography, said: 'The agreement underlines the great potential of the EBA technology. Roche Vitamins' leading market position and its history of innovation make it an ideal licence partner for UpFront Chromatography.'
Manfred Eggersdorfer, head of research and development of Roche Vitamins commented: 'The agreement with Upfront Chromatography gives us access to an innovative extraction technology. It offers potential for applications in many processes we develop.'